| Company Name: |
SuZhou Medinoah Co.,LTD.
|
| Tel: |
0512-69561983 13914027025 |
| Email: |
zhang_q@medinoah.com |
| Products Intro: |
Product Name:(4-{[(2S,5S)-2-{3-[(aminocarbonyl)amino]propyl}-12-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,4,7-trio
CAS:2504068-28-2
Purity:>95% Package:5g;10g;1kg;10kg;>10kg
|
| Company Name: |
Hangzhou Beiputai Biopharmaceutical Co., Ltd
|
| Tel: |
0571-85350119 15888826472 |
| Email: |
bptsales@163.com |
| Products Intro: |
Product Name:MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951)
CAS:2504068-28-2
Purity:98% Package:10mg;100mg;1g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:MC-Val-Cit-PAB-Exatecan
CAS:2504068-28-2
Package:50mg;5mg
|
| Company Name: |
Anhui JYHX CO., LTD.
|
| Tel: |
0551-68788198 13295518198 |
| Email: |
wangyanan@ahjyhx.com |
| Products Intro: |
Product Name:INDEX NAME NOT YET ASSIGNED
CAS:2504068-28-2
Purity:95% 96% 97% 98% 99% HPLC Package:1mg;10mg;100mg;500mg;1g;10g;100g;500g;900g Remarks:NULL
|
INDEX NAME NOT YET ASSIGNED manufacturers
|
| | INDEX NAME NOT YET ASSIGNED Basic information |
| Product Name: | INDEX NAME NOT YET ASSIGNED | | Synonyms: | MC-Val-Cit-PAB-DX8951;MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951);MC-Val-Cit-PAB-Exatecan;(4-{[(2S,5S)-2-{3-[(aminocarbonyl)amino]propyl}-12-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-1,4,7-trio | | CAS: | 2504068-28-2 | | MF: | C53H60FN9O12 | | MW: | 1034.1 | | EINECS: | | | Product Categories: | | | Mol File: | 2504068-28-2.mol |  |
| | INDEX NAME NOT YET ASSIGNED Chemical Properties |
| Boiling point | 1350.1±65.0 °C(Predicted) | | density | 1.45±0.1 g/cm3(Predicted) | | form | Solid | | pka | 10.74±0.40(Predicted) | | color | Light yellow to yellow |
| | INDEX NAME NOT YET ASSIGNED Usage And Synthesis |
| Biological Activity | MC-Val-Cit-PAB-DX8951 is a drug-linker conjugate for ADC. MC-Val-Cit-PAB-DX8951 is composed of a DNA topoisomerase I DX-8951 and a cathepsin cleavable ADC linker.
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1]. | | References | [1]. Anish Thomas, et al. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016 Jun;17(6):e254-e262. |
| | INDEX NAME NOT YET ASSIGNED Preparation Products And Raw materials |
|